Nigeria Sleeping Pills Market Size & Outlook, 2025-2033
Nigeria Sleeping Pills Market Insights
- As per Reed Intelligence insights, the Nigeria Sleeping Pills Market stood at USD 361.3 Million in 2024 and is anticipated to grow to USD 567.74 Million by 2033.
- The Nigeria market is expected to advance at a CAGR of 5.15% from 2025 through 2033.
- In 2024, Benzodiazepines accounted for the highest share of the By Product Type market size.
- During the forecast period, Benzodiazepines is set to register the highest growth, making it the most lucrative By Product Type segment.
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- In 2024, Nigeria accounted for 0.42% of the global Sleeping Pills Market size.
- By 2033, United States is expected to lead the global Sleeping Pills Market in terms of market size.
- Within Middle East and Africa, United Arab Emirates is projected to dominate the regional Sleeping Pills Market size by 2033.
- South Africa is identified as the fastest-growing market in Middle East and Africa, anticipated to reach USD 2344.14 Million by 2033.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2024 |
| Study Period | 2021-2033 |
| Historical Period | 2021-2023 |
| Forecast Period | 2025-2033 |
| Market Size In 2024 | USD 361.3 Million |
| Market Size In 2033 | USD 567.74 Million |
| Largest segment | Benzodiazepines |
| Units | Revenue in USD Million |
| CAGR | 5.15% (2025-2033) |
| Segmnetation Covered | |
| By Product Type |
|
| By Use |
|
| By Sleep Disorder |
|
| By Distribution Channel |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
Nigeria Sleeping Pills Market By Product Type 2025-2033 (USD Million)
| By Product Type | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Benzodiazepines | XX.x | XX.x | XX.x | 234.81 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Non-Benzodiazepines | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Nigeria Sleeping Pills Market By Use 2025-2033 (USD Million)
| By Use | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Short-term Use | XX.x | XX.x | XX.x | 228.02 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Long-term Use | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Nigeria Sleeping Pills Market By Sleep Disorder 2025-2033 (USD Million)
| By Sleep Disorder | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Insomnia | XX.x | XX.x | XX.x | 159.66 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Sleep disorder | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Restless leg syndrome narcolepsy | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Sleepwalking | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Nigeria Sleeping Pills Market By Distribution Channel 2025-2033 (USD Million)
| By Distribution Channel | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospital Pharmacies | XX.x | XX.x | XX.x | 197.13 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Retail Pharmacies and Drug Stores | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Online Pharmacies | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
